Insmed to Host First Quarter 2009 Confe... ( RICHMOND Va. April 23 /- Insmed Inc. ...)

Insmed to Host First Quarter 2009 Conference Call

Date:4/23/2009

RICHMOND, Va., April 23 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday, May 13th at 8:30 AM ET, to discuss its financial results for the first quarter 2009. Insmed intends to issue its quarterly financial results press release before the market opens on May 13th.

To participate in the live conference call, please dial 800-706-7748 (U.S. callers) or 617-614-3473 (international), and provide passcode 81641944. A live webcast of the call will also be available at http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=2174191. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on May 13th at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 62249241.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this rele
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
2. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
3. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
4. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
5. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
6. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
7. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
8. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
9. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
10. Insmed to Seek Shareholder Approval for Reverse Split
11. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants

Post Your Comments:

(Date:12/16/2009)... Corporation (Nasdaq: MATK ) today announced its financial ... October 31, 2009. Revenues for the fourth quarter were ... fourth quarter of fiscal 2008. Net income was $11.0 ... quarter of fiscal 2009, a 5% increase compared with ... year,s fourth quarter. The fourth quarter of fiscal ...

(Date:12/16/2009)... microgears in suspended solution by swimming , ... ... Scientists at the U.S. Department of Energy’s (DOE) Argonne National ... bacteria can turn microgears when suspended in a solution, providing ... , , ,“The gears are a million times more massive ...

(Date:12/16/2009)... WALTHAM, Mass., Dec. 16 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... Biotech/Janssen-Cilag,s Stelara and Abbott,s briakinumab (both interleukin inhibitors) ... in 2012 in the drug market for moderate ... will experience greater uptake, capturing nearly three times ...

(Date:12/16/2009)... Assessment with the Food and Drug Administration ... AEterna Zentaris Inc. (NASDAQ: AEZS ; ... company focused on oncology and endocrine therapy, ... Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of ... perifosine (KRX-0401), the Company,s PI3K/Akt pathway inhibitor, ...

[0] Martek Announces Fourth Quarter and FY 2009 Financial Results [0] Argonne Scientists Use Bacteria to Power Simple Machines [0] In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market [0] AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma

... SAN DIEGO, Oct. 1 Halozyme Therapeutics, Inc.,(Nasdaq: ... commercializing,products targeting the extracellular matrix, today announced that ... 8, beginning at 12:15 p.m. EDT. A,webcast of ... company website., PRESENTATIONS, -- Strategic Company ...

... Centers Open, EL SEGUNDO, Calif., Oct. 1 ... services in the United States, is,caring for thousands of ... people in the Houston area. DaVita,s Emergency Response Team,had ... deliver vital dialysis treatment during and after the storm. ...

... QUEBEC CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna ... a global biopharmaceutical company focused on,endocrine therapy ... patient,recruitment for the Company,s second efficacy trial ... hyperplasia (BPH), a non-cancerous enlargement of the,prostate, ...

Other Biology Technology:Halozyme Therapeutics to Host Research Day for Investors and Analysts 2 DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike 2 AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2 AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3 AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4

Halozyme Therapeutics to Host Research Day for Investors and Analysts DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

(Date:12/16/2009)... that short-term, seasonal exposure to pesticides in rivers ... of wild salmon populations. In addition to the ... that exposure to commonly used pesticides may further ... , "Major efforts are currently underway to ... recover depressed populations," says David Baldwin of the ...

(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...

(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin ... safety and finger-based biometric identification solutions, announced ... a Special Shareholder Meeting held today approved ... Division to Interact911 Mobile Systems Inc. Of ... favor and 1.2% were opposed. ,, (Logo: ...

Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2 iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2 BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2 BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3 Mapping the Link Between Alcohol Cancer 60159 1 Mapping the Link Between Alcohol Cancer 60159 2 Dr Lawrence Brown Named President of the Child Neurology Foundation 60155 1 Dr Lawrence Brown Named President of the Child Neurology Foundation 60155 2 PrepareCo com Introduces New Online Source for Emergency Self Reliant Food 26amp 3B Survival Products 60151 1 PrepareCo com Introduces New Online Source for Emergency Self Reliant Food 26amp 3B Survival Products 60151 2

[0] Even at sublethal levels, pesticides may slow the recovery of wild salmon populations [0] iQor Named to InfoWorld 100 List of Top IT Projects of 2009 [0] BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division

... in which one enzyme passes off a protein like a ... how cells control some vital functions, according to investigators at ... appears in the January 14 advanced online publication issue of ... simple chemical link between molecules called a thioester bond acts ...

... Jan. 23 State of the Union address, President George Bush ... oil by requiring the production of 35 billion gallons a ... times the current target set by Congress of 7.5 billion ... fuels derived from biological material. Currently, the main biofuel used ...

... cure for deafness. , As a leader in stem cell-based research ... Medicine, he's got a step-by-step plan for making this dream ... but if anyone can do it, he's the guy to ... we do this?'" said Heller, PhD, associate professor of otolaryngology, ...

Other Biology News:Chemical switch triggers critical cell activities 2 Chemical switch triggers critical cell activities 3 Cellulosic ethanol: Fuel of the future? 2 Cellulosic ethanol: Fuel of the future? 3 Stem cell transplants explored at Stanford as a possible treatment for hearing loss 2 Stem cell transplants explored at Stanford as a possible treatment for hearing loss 3

Chemical switch triggers critical cell activities Cellulosic ethanol: Fuel of the future?Stem cell transplants explored at Stanford as a possible treatment for hearing loss

... Proliferation Marker, prediluted Ki67 antigen is ... expressed by proliferating cells in all phases ... G2 and M phase). It is absent ... useful in establishing the cell growing fraction ...

UBC13 Antibody...

Request Info...

HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....

Biology Products:

Rabbit Anti-Ki67 Polyclonal Antibody, Unconjugated from GeneTex Rabbit Anti-UBC13 Polyclonal Antibody, Unconjugated from ProSci, Inc 10% BSA in TBS from Upstate Mouse Anti-Human HLA II DG+DR+DP Monoclonal Antibody, Unconjugated, Clone IQU9 from Diaclone

Insmed to Host First Quarter 2009 Confe...( RICHMOND Va. April 23 /- Insmed Inc. ...)